MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-13-2025
Brainsway Ltd. General and Administrative Expenses 2011-2025 | BWAY
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Brainsway Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 5.78 M | 3.31 M | 4.39 M | 8.23 M | 7.47 M | 5.74 M | 3.61 M | 2.34 M | 1.43 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.23 M | 1.43 M | 4.7 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 20.97 | -1.38 % | $ 226 M |  China |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Co-Diagnostics
CODX
|
14.3 M | $ 0.23 | -4.4 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 39.53 | -1.4 % | $ 1.1 B | USA |
 |
BioNano Genomics
BNGO
|
51.9 M | $ 1.52 | - | $ 1.93 M | USA |
 |
DarioHealth Corp.
DRIO
|
18.1 M | $ 10.17 | 1.29 % | $ 289 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
1.19 B | $ 67.51 | 0.13 % | $ 26.1 B | USA |
 |
Danaher Corporation
DHR
|
7.76 B | $ 230.0 | -0.45 % | $ 168 B | USA |
 |
Exact Sciences Corporation
EXAS
|
191 M | $ 101.56 | 0.02 % | $ 18.8 B | USA |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 26.78 | -0.85 % | $ 810 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
118 M | $ 19.47 | -1.32 % | $ 1.05 B | USA |
 |
Celcuity
CELC
|
9.06 M | $ 101.9 | -0.7 % | $ 4.02 B | USA |
 |
Anixa Biosciences
ANIX
|
7.44 M | $ 3.21 | -6.25 % | $ 102 K | USA |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
1.99 B | $ 226.52 | 0.26 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
180 M | $ 103.35 | 0.94 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
276 M | $ 6.44 | -1.68 % | $ 583 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 135.12 | -0.15 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
751 M | $ 203.88 | - | $ 10.5 B | USA |
 |
ENDRA Life Sciences
NDRA
|
7.06 M | $ 4.94 | -3.14 % | $ 2.65 M | USA |
 |
Neogen Corporation
NEOG
|
218 M | $ 7.12 | -0.35 % | $ 1.54 B | USA |
 |
National Research Corporation
NRC
|
46.6 M | $ 18.74 | 0.46 % | $ 460 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 176.16 | 0.15 % | $ 19.6 B | USA |
|
Biodesix
BDSX
|
80.5 M | $ 6.76 | -0.88 % | $ 877 M | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 254.32 | 0.02 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 182.75 | -0.51 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
442 M | $ 688.22 | 0.01 % | $ 56.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
170 M | $ 1.77 | -5.85 % | $ 449 M | USA |
 |
Lantheus Holdings
LNTH
|
194 M | $ 66.73 | 0.07 % | $ 4.62 B | USA |
 |
Mettler-Toledo International
MTD
|
936 M | $ 1 419.64 | 0.11 % | $ 30.1 B |  Schweiz |
 |
Agilent Technologies
A
|
1.62 B | $ 138.31 | 0.03 % | $ 42 B | USA |
 |
Biomerica
BMRA
|
2.98 M | $ 2.7 | 1.9 % | $ 6.2 M | USA |
 |
Bioventus
BVS
|
304 M | $ 7.4 | 0.27 % | $ 464 M | USA |
 |
NeoGenomics
NEO
|
260 M | $ 12.33 | 0.2 % | $ 1.56 B | USA |